Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Pulmicort pMDI HFA · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Pulmicort pMDI |
| 2 | EXPERIMENTAL | Budesonide pMDI |
| 3 | EXPERIMENTAL | Budesonide pMDI + Aerochamber Zero-stat spacer |
| 4 | EXPERIMENTAL | Pulmicort repulses via Spira Nebuliser |
| 5 | EXPERIMENTAL | Pulmicort Turbohaler |
| Name | Type | Description |
|---|---|---|
| Pulmicort pMDI HFA | DRUG | Inhalation aerosol, 200 μg/ metered dose. Each subject receive a single dose from 4 inhalations |
| Budesonide pMDI HFA | DRUG | Inhalation aerosol, 160 μg/ metered dose. Each subject receive a single dose from 4 inhalations |
| Pulmicort Repulses | DRUG | Suspension for nebulisation, 0.5 mg/mL. Each subject receive a single dose from 100 inhalations |
| Pulmicort Turbohaler | DRUG | Inhaled powder, 200 μg/ metered dose. Each subject receive a single dose from 4 inhalations |
Inclusion Criteria: * Provision of informed consent prior to any study specific procedures * BMI between 18 and 30 kg/m2 * Non-smokers/non-snuffers Exclusion Criteria: * Pregnant and/or lactating women * Use of oral contraceptives or hormonal implants * Known or suspected hypersensitivity to gluc...
Pulmicort pMDI HFA is an investigational pressurized metered dose inhaler formulation developed by AstraZeneca PLC. It is a small molecule product delivered by inhalation and has been studied in a Phase 1 trial in healthy volunteers. Its specific therapeutic indications have not been disclosed.
Pulmicort pMDI HFA is developed by AstraZeneca PLC, which trades under the ticker AZN. AstraZeneca is the sponsor of the clinical program for this inhaled product.
Pulmicort pMDI HFA is in Phase 1 clinical development. One Phase 1 trial has been completed, and no trials are currently active. It is an investigational product and is not described as approved by the FDA.
Pulmicort pMDI HFA has been studied in one completed Phase 1 trial, NCT00975754, titled Lung Deposition Via Different Inhalation Devices. The trial enrolled 16 healthy volunteers in Sweden, was randomized and controlled, and included participants aged 18 years and older of all sexes.
The therapeutic indications for Pulmicort pMDI HFA have not been disclosed. The completed Phase 1 trial, NCT00975754, evaluated lung deposition via different inhalation devices in healthy volunteers rather than in a patient population with a specific disease.
Pulmicort pMDI HFA is administered by inhalation as a pressurized metered dose inhaler. Its completed Phase 1 trial, NCT00975754, compared lung deposition via different inhalation devices, which reflects the inhaled route of delivery for this small molecule product.